Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases

Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hingorani, Mohan, Dixit, Sanjay, Pugazhenthi, Pattu, Hawkyard, Simon, Robertson, Andrew, Khafagy, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383847/
https://www.ncbi.nlm.nih.gov/pubmed/25859413
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.0025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383847/
https://www.ncbi.nlm.nih.gov/pubmed/25859413
http://dx.doi.org/10.7497/j.issn.2095-3941.2014.0025

Ejemplares similares